FDA Approves Aphexda for Use in Stem Cell Mobilization
September 12th 2023In clinical trials, Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal to enable stem cell transplantation for patients with multiple myeloma. It will have a list price 5,900 per vial, with most patients needing two vials for treatment.
X4 Pharmaceuticals Submits NDA of Mavorixafor for Rare Immunodeficiency Disease
September 5th 2023If approved, mavorixafor would be the first therapy to address the genetic defect that results in WHIM syndrome, an ultra-rare disease that can cause recurrent lung infections, papillomavirus-related warts, and an increased risk of developing certain types of cancer.